PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Alternative Drug Delivery Systems Key for European hGH Market - New analysis from Frost & Sullivan, European Human Growth Hormone Market, finds that the market generated revenues of $846.4 million in 2007 and is estimated to grow at a compound annual growth rate (CAGR) of 2.4 per cent for the period 2007-2014
Alternative Drug Delivery Systems Key for European hGH Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/09/10 - New analysis from Frost & Sullivan, European Human Growth Hormone Market, finds that the market generated revenues of $846.4 million in 2007 and is estimated to grow at a compound annual growth rate (CAGR) of 2.4 per cent for the period 2007-2014.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With the approval of biosimilars in Europe, the overall cost of human growth hormone (hGH) treatment has reduced by more than 25 per cent. Manufacturers are now more likely to take initiatives to obtain marketing approval from EMEA for other indications and to increase research in alternative drug delivery methods to combat pricing pressures from biosimilars. The success of these initiatives will be crucial for growth in the European hGH market.

New analysis from Frost & Sullivan (pharma.frost.com), European Human Growth Hormone Market, finds that the market generated revenues of $846.4 million in 2007 and is estimated to grow at a compound annual growth rate (CAGR) of 2.4 per cent for the period 2007-2014.

"Currently, hGH treatment is approved for only five medical conditions in Europe," notes Frost & Sullivan Research Analyst Prabakar Sampath. "Further growth of the European hGH market depends on the EMEA's approval of hGH treatment for new indications such as cachexia and achondroplasia."

While the U.S. Food and Drug Administration (FDA) has approved hGH treatment for several conditions including cachexia, EMEA demands strict scientific evidence for the efficacy of hGH in these conditions. Even though research is underway to prove the efficacy of somatropin in several other indications, manufacturers are reluctant to file for marketing approval ever since the EMEA declined approval for Serostim, Merck-Serono's hGH product for AIDS-related wasting.

The biochemical nature of hGH shows that the treatment is more effective when the protein is injected into the blood stream using a hypodermic needle. Therefore, developing alternative drug delivery methods is one of the most important challenges for manufacturers.

"One of the chief competitive factors for hGH products is the delivery method, which represents an avenue for product differentiation," remarks Sampath. "Alternative drug delivery methods could increase the market size by attracting more users, particularly considering that the majority of hGH users are children below the age of fifteen and that hGH injections have to be given daily."

Manufacturers need to form strategic partnerships with drug delivery design companies to facilitate somatropin delivery through oral and transdermal means. Such products would be a blessing for needle-apprehensive children and adults who need to be injected every day.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European hGH market, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]rost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

European Human Growth Hormones Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services Programme, which also includes research in the following markets: European Biosimilars Market Outlook, European Therapeutic Monoclonal Antibodies Market, European Emerging Generic Pharmaceuticals Market and European Vaccines Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

European Human Growth Hormones Market
H048

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Alternative Drug Delivery Systems Key for European hGH Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)